{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab+deruxtecan&page=7", "query": { "intervention": "trastuzumab deruxtecan", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab+deruxtecan&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab+deruxtecan&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T21:15:12.128Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Gastrointestinal Cancer", "HER2 Gene Mutation" ], "interventions": [ { "name": "Neratinib Pill", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-06-24", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 3, "location_summary": "Palo Alto, California • Buffalo, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Buffalo", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274048" }, { "nct_id": "NCT06899126", "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Platinum Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 686, "start_date": "2025-10-24", "completion_date": "2032-11-24", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 26, "location_summary": "Anchorage, Alaska • Fountain Valley, California • Los Angeles, California + 22 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06899126" }, { "nct_id": "NCT05950945", "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2023-12-30", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Tampa, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Summit", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05950945" }, { "nct_id": "NCT06525298", "title": "EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Homologous Recombination Deficiency", "HRR Deficiency" ], "interventions": [ { "name": "EIS-12656", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisbach Bio GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2024-09-09", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06525298" }, { "nct_id": "NCT05376878", "title": "An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain" ], "interventions": [ { "name": "Copper Cu 64-DOTA-Trastuzumab", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "DEVICE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DEVICE", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-12-21", "completion_date": "2027-04-27", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05376878" }, { "nct_id": "NCT06467357", "title": "Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 620, "start_date": "2024-08-12", "completion_date": "2029-05-16", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 48, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06467357" }, { "nct_id": "NCT06533826", "title": "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-low Breast Cancer", "Metastatic Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Datopotamab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ana C Garrido-Castro, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 357, "start_date": "2024-10-29", "completion_date": "2038-08-01", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533826" }, { "nct_id": "NCT07578116", "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic HER2-Positive Breast Carcinoma", "Oligometastatic Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Breast Conservation Treatment", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclin-Dependent Kinase 4 Inhibitor", "type": "DRUG" }, { "name": "Cyclin-Dependent Kinase 6 Inhibitor", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "HER2-targeted Therapy", "type": "DRUG" }, { "name": "Hormone Therapy", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Boost", "type": "RADIATION" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Taxane Compound", "type": "DRUG" }, { "name": "Total Mastectomy", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 562, "start_date": "2027-03-09", "completion_date": "2033-05-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 59, "location_summary": "Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Greenwich", "state": "Connecticut" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07578116" }, { "nct_id": "NCT06961331", "title": "Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic HER2+ Advanced Breast Cancer" ], "interventions": [ { "name": "Tucatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2025-05-07", "completion_date": "2025-09-25", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06961331" }, { "nct_id": "NCT04585958", "title": "Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2021-05-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-24T21:15:12.128Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Coral Gables, Florida • Deerfield Beach, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Doral", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585958" } ] }